Wuhan Easy Diagnosis Biomedicine Co.,Ltd. announced that it expects to receive CNY 846.1958 million in funding
November 18, 2020
Share
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SZSE:002932) announced a private placement of not more than 20,701,544 A shares for gross proceeds of no more than CNY 846,195,800 on November 19, 2020. The company will issue shares at a price of not lower than 80% of the median market price of the company’s shares as of 20 previous days to issuance date. The transaction will include participation from no more than 35 specific investors. The transaction has been approved by the board of directors of the company at its 14th meeting of the 3rd directorate of the company. The transaction is subject to approval from company’s shareholders meeting and China Securities Regulatory Commission. The shares issued are subject to a hold period of 6 months from the date of issuance. The transaction will be valid for 12 months since approval from the shareholders’ meeting of the company.
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is a China-based company which is mainly engaged in research and development, manufacture and sales of Point of Care Testing (POCT) rapid diagnostic reagents and quick testing instruments. The Company's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The Company's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.